Use Of Nivolumab (N) And Cabozantinib (C) For Treatment Of The Metastatic Renal Cell Carcinoma (Mrcc) In The Veneto Region: Results Of Amour Study.

Marco Maruzzo,Alberto Bortolami,Dario Palleschi,Andrea Zivi,Maurizio Nicodemo,Donata Sartori,Rocco De Vivo,Fable Zustovich,Davide Bimbatti,Davide Pastorelli,Giuseppe Dione Vultaggio,Mariella Soraru,Melissa Ballestrin, Giulia Zanchetta,Caterina Modonesi,Paola Randisi,Carmen Barile,Gino Perri,Umberto Basso,Vittorina Zagonel

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 1|浏览11

暂无评分

摘要

290Background: Second (2L) or third-line (3L) treatment options for mRCC have dramatically changed in the last years. The standard of care as per Italian Regulatory Agencies approvals is N or C. To...

查看译文

关键词

Nivolumab,Cabozantinib,Renal cell carcinoma,Oncology,Medicine,Internal medicine,Standard of care,Treatment options

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要